読み込み中
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
最新データ
$6.34
+$0.13 · +2.09%
日中の時刻はETです。市場データは遅延する場合があります。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
38
割高
センチメント
60
まちまち
リスク
40
中程度のリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$28.67
上昇余地（352.21%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1083.56万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM528.1万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF353.43万0.00%954億 USD0.05%$235+0.80%
Vanguard U.S. Momentum Factor ETFVFMO313.18万0.16%19億 USD0.13%$230.11+1.02%
State Street SPDR S&P Pharmaceuticals ETFXPH286.93万0.62%4.62億 USD0.35%$64.65+1.60%
Vanguard Russell 2000 ETFVTWO192.27万0.01%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB152.21万0.01%102.79億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS136.51万0.00%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
